The scientist’s investigation covers issues in Microbiology, Fluconazole, Candida albicans, Corpus albicans and Voriconazole. Microbiology and Mycosis are frequently intertwined in his study. Richard J. Hollis combines subjects such as Echinocandin and Caspofungin with his study of Mycosis.
His research in Fluconazole intersects with topics in Broth microdilution and Candida glabrata. His research on Candida albicans often connects related areas such as Itraconazole. His study looks at the relationship between Corpus albicans and fields such as Drug resistance, as well as how they intersect with chemical problems.
His scientific interests lie mostly in Microbiology, Fluconazole, Broth microdilution, Typing and Voriconazole. His work on Microbiology is being expanded to include thematically relevant topics such as Pulsed-field gel electrophoresis. The study incorporates disciplines such as Amphotericin B, Minimum inhibitory concentration, Mycosis and Cryptococcus neoformans in addition to Fluconazole.
His work deals with themes such as Caspofungin, Agar, Etest, Candida spp and Drug resistance, which intersect with Broth microdilution. His Typing study combines topics in areas such as Infection control, Restriction enzyme, Outbreak, Staphylococcus aureus and Restriction fragment. As a part of the same scientific study, Richard J. Hollis usually deals with the Voriconazole, concentrating on Aspergillus and frequently concerns with Aspergillus fumigatus and Aspergillus terreus.
Richard J. Hollis focuses on Microbiology, Broth microdilution, Fluconazole, Voriconazole and Posaconazole. His study looks at the relationship between Microbiology and topics such as Mycosis, which overlap with Surrogate endpoint. His study in Broth microdilution is interdisciplinary in nature, drawing from both Agar, Drug resistance and Etest.
His Fluconazole study incorporates themes from Amphotericin B, Candida glabrata and Cryptococcus neoformans. He combines subjects such as Itraconazole, Potency and Aspergillus with his study of Voriconazole. As part of the same scientific family, Richard J. Hollis usually focuses on Caspofungin, concentrating on Micafungin and intersecting with Echinocandin.
His primary areas of investigation include Microbiology, Fluconazole, Fungi imperfecti, Caspofungin and Broth microdilution. Microbiology connects with themes related to Mycosis in his study. His work carried out in the field of Fluconazole brings together such families of science as Candida parapsilosis, Amphotericin B and Candida glabrata.
His research investigates the connection between Caspofungin and topics such as Drug resistance that intersect with problems in Patient age. Richard J. Hollis works mostly in the field of Broth microdilution, limiting it down to concerns involving Cryptococcus neoformans and, occasionally, Potency and Cryptococcosis. His Voriconazole study integrates concerns from other disciplines, such as Aspergillus fumigatus, Itraconazole, Cross-resistance and Aspergillus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
M. A. Pfaller;D. J. Diekema;R. N. Jones;H. S. Sader.
Journal of Clinical Microbiology (2001)
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
Sandra S. Richter;Rudolph P. Galask;Shawn A. Messer;Richard J. Hollis.
Journal of Clinical Microbiology (2005)
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
M. A. Pfaller;S. A. Messer;R. J. Hollis;R. N. Jones.
Antimicrobial Agents and Chemotherapy (2002)
Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998
Pfaller;R N Jones;G V Doern;H S Sader.
Antimicrobial Agents and Chemotherapy (2000)
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
M. A. Pfaller;L. Boyken;R. J. Hollis;J. Kroeger.
Journal of Clinical Microbiology (2008)
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
D. J. Diekema;S. A. Messer;R. J. Hollis;R. N. Jones.
Journal of Clinical Microbiology (2003)
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment
David R. Reagan;Bradley N. Doebbeling;Michael A. Pfaller;Carol T. Sheetz.
Annals of Internal Medicine (1991)
Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000
M. A. Pfaller;D. J. Diekema;R. N. Jones;S. A. Messer.
Journal of Clinical Microbiology (2002)
International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program
M. A. Pfaller;R. N. Jones;G. V. Doern;H. S. Sader.
Journal of Clinical Microbiology (1998)
International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
M.A Pfaller;R.N Jones;G.V Doern;A.C Fluit.
Diagnostic Microbiology and Infectious Disease (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
JMI Laboratories
JMI Laboratories
University of Iowa Hospitals and Clinics
Virginia Commonwealth University
JMI Laboratories
Arizona State University
JMI Laboratories
University of Iowa
Heidelberg University
Virginia Commonwealth University Medical Center
Seoul National University
University of Michigan–Ann Arbor
Texas A&M University
Technical University of Munich
Northwestern University
Oak Ridge National Laboratory
Monash University
Victoria University of Wellington
National Institutes of Health
University of Valladolid
The University of Texas Health Science Center at Houston
University of California, San Francisco
New York University
West Virginia University
Tufts University
ETH Zurich